Has Jay Traverse, MD received payments from drug or device companies?

Yes. Drug and device makers reported $198,336 in general payments to Jay Traverse, MD across 235 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jay Traverse, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jay Traverse, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jay Traverse, MD

Interventional Cardiology · Minneapolis, MNNPI 1306807458

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $183,411 of the $198,336 with a category attached, or 92.5%. Abbott accounts for 72.1% of it on its own, with 16 other manufacturers making up the rest. Among interventional cardiology clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$198,336in general payments, 2019–2025

Across 235 payments — averaging $843.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$143K
Bard Peripheral Vascular, Inc.$25K
Boehringer Ingelheim$15K
ZOLL Circulation Inc$12K
Bayer$1K
C. R. Bard, Inc. & Subsidiaries$750
plus $1K from 11 others

$126,225in research payments, 2019–2025

Across 12 payments — averaging $10,519 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Shockwave Medical, Inc$125K
Bard Peripheral Vascular, Inc.$1K

What the payments were for

Consulting fees$183,41192%
Speaking & faculty fees$8,7504%
Travel & lodging$3,4962%
Food & beverage$2,6671%
Education$120%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	170	$142,932
Bard Peripheral Vascular, Inc.	13	$24,959
Boehringer Ingelheim	8	$15,253
ZOLL Circulation Inc	16	$11,727
Bayer	11	$1,314
C. R. Bard, Inc. & Subsidiaries	2	$750
Abiomed	2	$256
Biocardia, Inc.	1	$250
Edwards Lifesciences	2	$217
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	1	$217
Medtronic	2	$185
Heartflow, Inc.	1	$151
Boston Scientific	1	$45
Johnson & Johnson	2	$29
Novo Nordisk	1	$20
Irhythm Technologies, Inc.	1	$19
Chiesi USA, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

AMPLATZER Occluders$69,650
AMPLATZER AMULET$36,200
AMPLATZER PICCOLO$14,500
AMPLATZER$12,100
TherOx DS2 Console$11,430
Catheter$11,430
Downstream Cartridge$11,430
AMPLATZER Vascular Plug and Accs$5,338
MitraClip$2,200
LUTONIX$1,500
THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,400
MitraClip System$350
Diamondback Coronary$350
Impella$256
LifeVest$217
SAPIEN 3 Ultra RESILIA$180
Telescope$158
FFRct$151

How this compares

$198,336 in reported general payments places this provider in the 90th percentile of 84 interventional cardiology providers in Minnesota.

See all interventional cardiology providers in Minnesota →

Medicare billing

Part B allowed, 2024

$72,791

Medicare patients

294

Services billed

507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	56	$66,145
EntrestoSacubitril/Valsartan	40	$38,714
Repatha SureclickEvolocumab	13	$12,482
Ranolazine ErRanolazine	30	$3,058
Metoprolol Succinate	102	$2,097
Atorvastatin Calcium	135	$1,877
Rosuvastatin Calcium	97	$1,343
Lisinopril	93	$1,218
Isosorbide Mononitrate ErIsosorbide Mononitrate	53	$941
Carvedilol	83	$829
ClopidogrelClopidogrel Bisulfate	47	$666
Losartan Potassium	46	$634
Flecainide Acetate	14	$623
Diltiazem 24hr Er (Cd)Diltiazem Hcl	17	$580
Amlodipine Besylate	69	$500

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Minneapolis

Emmanouil BrilakisMinneapolis$548K
Wesley PedersenMinneapolis$493K
Michael ManolesMinneapolis$201K
Robert WilsonMinneapolis$176K
Yale WangMinneapolis$168K
Steven RohMinneapolis$67K
Stefan BertogMinneapolis$64K
Konstantinos VoudrisMinneapolis$46K
Michael MooneyMinneapolis$25K
Alok SharmaMinneapolis$21K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →